GLA Scientific Advisory Board Member, Paul Arnaboldi, Ph.D has been collaborating with multiple researchers to develop a rapid Lyme disease test that delivers results in 20 minutes from a small blood sample. This test could speed up diagnosis and treatment, but further development is needed before it’s available to health care providers.
GLA Scientific Advisory Board Member, Paul Arnaboldi, Ph.D. from NY State Medical College and Biopeptides Corp, has been collaborating with University of California, Los Angeles (UCLA) researchers at to develop a single-tier Lyme disease diagnostic test. This test, known as xVFA, requires only a small blood sample and can return results within 20 minutes. They tested their prototype with blood samples from the Lyme Disease Biobank and Centers for Disease Control and Prevention. With low manufacturing costs and 95.5% sensitivity and 100% specificity, this technology holds promise, as reported in a recent study published in Nature Communications.
Unlike the traditional two-tiered testing approach, which requires patient samples to be sent to centralized labs, xVFA offers a single, point-of-care test that could drastically reduce the waiting time for results. This advancement could streamline Lyme disease diagnosis, allowing faster treatment for patients. While this technology shows great potential, it could take a few years before it becomes widely available in clinics as further testing, scaling up production, and development are necessary.
Read more about the study here: Lyme disease early detection could get boost from simpler, faster testing technology | UCLA
Publication: Rapid single-tier serodiagnosis of Lyme disease | Nature Communications
***